Artificial Intelligence Archives - Page 32 of 35

July 9, 2023 Artificial Intelligence FDAcop

Regulatory Experts Provide an Exclusive Analysis on Life Sciences

The FDA’s Office of Pharmaceutical Quality (OPQ) has recently released a report titled “State of Pharmaceutical Quality,” which aims to provide insight into the current state of quality in the pharmaceutical industry. However, upon closer analysis by AgencyIQ, it becomes apparent that the report is lacking in certain areas and contains some potentially misleading information. […]

July 8, 2023 Artificial Intelligence FDAcop

FDA Releases Draft Guidelines for Decreasing Microbial Contamination in Tattoo Inks

The U.S. Food and Drug Administration (FDA) has issued a draft guidance to help manufacturers and distributors prevent microbial contamination in tattoo inks. With approximately 30 percent of people in the U.S. having a tattoo, it is important to ensure that tattoo inks are free of contamination to prevent infections and serious injuries. The FDA […]

July 8, 2023 Artificial Intelligence FDAcop

FDA News Roundup: June 13, 2023

The U.S. Food and Drug Administration (FDA) has released a summary of recent news from the agency. One of the highlights is the publication of an article by Kerry Jo Lee, M.D., Associate Director for Rare Diseases at the FDA, on the Accelerating Rare disease Cures (ARC) Program. The ARC Program aims to increase the […]

July 8, 2023 Artificial Intelligence FDAcop

Bausch + Lomb Remains on Acquisition Path: Buys J&J Eye Drops for $106M

Bausch + Lomb, a global eye care company, is expanding its over-the-counter presence by acquiring Johnson & Johnson’s Blink line of eye drops for $106.5 million. The acquisition includes the Blink product line, which consists of six eye drops and contact lens drops for rewetting and lubricating the eye. Bausch + Lomb will finance the […]

July 8, 2023 Artificial Intelligence FDAcop

FDA Updates: June 16, 2023

The U.S. Food and Drug Administration (FDA) has provided an at-a-glance summary of news from around the agency. Here are some key highlights: 1. COVID-19 Vaccine Formulation for Fall/Winter 2023-2024: The FDA has advised COVID-19 vaccine manufacturers to develop vaccines with a monovalent XBB.1.5 composition for the upcoming fall and winter seasons. The agency expects […]

July 8, 2023 Artificial Intelligence FDAcop

Exclusive Article – Expressing Gratitude

A new report from the E.U. Big Data Steering Group (BDSG), EMA, and the European Medicines Regulatory Network (EMRN) shares experience obtained from real-world data (RWD) based studies between September 2021 and February 2023. The aim of the study was to establish a workable framework for using real-world evidence (RWE) for regulatory cases within the […]

July 8, 2023 Artificial Intelligence FDAcop

FDA Initiates Pilot Program to Mitigate Risks in Utilizing Laboratory Developed Tests for Cancer Biomarker Identification

The U.S. Food and Drug Administration (FDA) has launched a new voluntary pilot program aimed at improving the selection of cancer treatments for patients. The program focuses on certain oncology drug products used with corresponding in vitro diagnostic tests. These tests provide essential information for the safe and effective use of specific cancer treatments. The […]

July 7, 2023 Artificial Intelligence FDAcop

Latest FDA Updates: July 7, 2023

The U.S. Food and Drug Administration (FDA) has released a summary of recent news and updates from the agency. One of the highlights is “Operation Broader Sword”, a joint enforcement operation between the U.S. and the Government of India to identify and stop the shipment of illicit pharmaceuticals, devices, and precursor chemicals through the international […]

July 7, 2023 Artificial Intelligence FDAcop

Recap of FDA Updates: June 20, 2023

The U.S. Food and Drug Administration (FDA) has released an at-a-glance summary of recent news and updates from the agency. One of the key updates is the FDA’s report on the occurrence of foodborne illness risk factors in fast food and full-service restaurants. According to the Centers for Disease Control and Prevention (CDC), over half […]

July 7, 2023 Artificial Intelligence FDAcop

FDA Gives Approval for New Class of Medications to Treat Type 2 Diabetes in Pediatric Patients

The U.S. Food and Drug Administration (FDA) has approved two medications, Jardiance and Synjardy, as treatment options for children aged 10 and older with type 2 diabetes. This is significant, as children with type 2 diabetes have limited treatment options compared to adults. Type 2 diabetes is a chronic condition where the body does not […]

Category: Artificial Intelligence